Creabilis SA is a biopharmaceutical company creating innovative new drugs to tackle unmet medical needs in dermatology and inflammatory diseases.

The company’s lead product is CT327, a novel topically applied TrkA kinase inhibitor in Phase II clinical trials in psoriasis and atopic dermatitis.

The company’s portfolio also includes CT340, a potent TrkA kinase inhibitor for the treatment of conditions in which TrkA kinase inhibition is implicated, including inflammatory arthritis and pain and CT637, a new approach to the treatment of significant inflammatory conditions such as rheumatoid arthritis.